PT  - JOURNAL ARTICLE
AU  - Reindl, Markus
AU  - Schanda, Kathrin
AU  - Woodhall, Mark
AU  - Tea, Fiona
AU  - Ramanathan, Sudarshini
AU  - Sagen, Jessica
AU  - Fryer, James P.
AU  - Mills, John
AU  - Teegen, Bianca
AU  - Mindorf, Swantje
AU  - Ritter, Nora
AU  - Krummrei, Ulrike
AU  - Stöcker, Winfried
AU  - Eggert, Juliane
AU  - Flanagan, Eoin P.
AU  - Ramberger, Melanie
AU  - Hegen, Harald
AU  - Rostasy, Kevin
AU  - Berger, Thomas
AU  - Leite, Maria Isabel
AU  - Palace, Jacqueline
AU  - Irani, Sarosh R.
AU  - Dale, Russell C.
AU  - Probst, Christian
AU  - Probst, Monika
AU  - Brilot, Fabienne
AU  - Pittock, Sean J.
AU  - Waters, Patrick
TI  - International multicenter examination of MOG antibody assays
AID  - 10.1212/NXI.0000000000000674
DP  - 2020 Mar 05
TA  - Neurology - Neuroimmunology Neuroinflammation
PG  - e674
VI  - 7
IP  - 2
4099  - http://nn.neurology.org/content/7/2/e674.short
4100  - http://nn.neurology.org/content/7/2/e674.full
SO  - Neurol Neuroimmunol Neuroinflamm2020 Mar 05; 7
AB  - Objective To compare the reproducibility of 11 antibody assays for immunoglobulin (Ig) G and IgM myelin oligodendrocyte glycoprotein antibodies (MOG-IgG and MOG-IgM) from 5 international centers.Methods The following samples were analyzed: MOG-IgG clearly positive sera (n = 39), MOG-IgG low positive sera (n = 39), borderline negative sera (n = 13), clearly negative sera (n = 40), and healthy blood donors (n = 30). As technical controls, 18 replicates (9 MOG-IgG positive and 9 negative) were included. All samples and controls were recoded, aliquoted, and distributed to the 5 testing centers, which performed the following antibody assays: 5 live and 1 fixed immunofluorescence cell-based assays (CBA-IF, 5 MOG-IgG, and 1 MOG-IgM), 3 live flow cytometry cell-based assays (CBA-FACS, all MOG-IgG), and 2 ELISAs (both MOG-IgG).Results We found excellent agreement (96%) between the live CBAs for MOG-IgG for samples previously identified as clearly positive or negative from 4 different national testing centers. The agreement was lower with fixed CBA-IF (90%), and the ELISA showed no concordance with CBAs for detection of human MOG-IgG. All CBAs showed excellent interassay reproducibility. The agreement of MOG-IgG CBAs for borderline negative (77%) and particularly low positive (33%) samples was less good. Finally, most samples from healthy blood donors (97%) were negative for MOG-IgG in all CBAs.Conclusions Live MOG-IgG CBAs showed excellent agreement for high positive and negative samples at 3 international testing centers. Low positive samples were more frequently discordant than in a similar comparison of aquaporin-4 antibody assays. Further research is needed to improve international standardization for clinical care.ADEM=acute disseminated encephalomyelitis; AQP4=aquaporin-4; CBA=cell-based assay; FACS=fluorescence-activated cell sorting; IF=immunofluorescence; IfQ=Institute for Quality Assurance; Ig=immunoglobulin; MOG=myelin oligodendrocyte glycoprotein; NMOSD=neuromyelitis optica spectrum disorder